| Citation: |
WANG Mingbang, CHEN Changsha, LIU Rongzhen, XU Jianfeng. Effect of transurethral plasmakinetic resection of prostate in treating benign prostatic hyperplasia complicated with hypertension[J]. Journal of Clinical Medicine in Practice, 2024, 28(15): 90-94. DOI: 10.7619/jcmp.20241211
|
To compare the effects of transurethral plasmakinetic resection of prostate (TUPKRP) and drug therapy on blood pressure and change of blood pressure rhythm in patients with benign prostatic hyperplasia complicated with hypertension.
A total of 103 patients with benign prostatic hyperplasia in the hospital from June 2021 to June 2023 were retrospectively enrolled as study objects. According to different treatment protocols, they were divided into drug therapy group with 47 cases (treated with telmisartan combined with finasteride) and surgical treatment group with 56 cases (treated with telmisartan combined with TUPKRP). Blood pressure levels (24-hour mean diastolic blood pressure, 24-hour mean systolic blood pressure, daytime mean diastolic blood pressure, daytime mean systolic blood pressure, nighttime mean diastolic blood pressure, nighttime mean systolic blood pressure), change of blood pressure rhythm (dipper blood pressure), prostate symptoms, prostate volume, residual urine volume, and sexual function were compared between the two groups before treatment and at 3 and 6 months after treatment.
The mean blood pressure at different time points in the surgical treatment group was significantly lower than that in the drug therapy group at 3 and 6 months after treatment (P < 0.05). The conversion rates of dipper blood pressure in the surgical treatment group at 3 and 6 months after treatment were 67.86% and 87.50%, which were significantly higher than 40.42% and 68.09% in the drug therapy group (P < 0.05). International Prostate Symptom Score (IPSS), residual urine volume, and prostate volume in the surgical treatment group were significantly lower than those in the drug therapy group at 3 and 6 months after treatment (P < 0.05). There was no significant difference in sexual function between the two groups before treatment and at 3 and 6 months after treatment (P>0.05).
Telmisartan combined with TUPKRP can reduce blood pressure levels, regulate change of blood pressure rhythm, improve prostate symptoms, reduce prostate volume, and decrease residual urine volume in patients with benign prostatic hyperplasia complicated with hypertension, with minimal impact on sexual function.
| [1] |
LERNER L B, MCVARY K T, BARRY M J, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: aua guideline part i-initial work-up and medical management[J]. J Urol, 2021, 206(4): 806-817. doi: 10.1097/JU.0000000000002183
|
| [2] |
董新强, 孙文功, 崔洪权, 等. 前列腺扩裂术对良性前列腺增生患者性功能的影响[J]. 实用临床医药杂志, 2020, 24(2): 65-67, 71. doi: 10.7619/jcmp.202002019
|
| [3] |
李鑫, 王文生, 李保国, 等. HoLEP、TUPKEP及TURP术治疗原发性高血压合并BPH的疗效分析及对炎性因子和血清PS A水平的影响[J]. 中国医学装备, 2020, 17(1): 96-100. doi: 10.3969/J.ISSN.1672-8270.2020.01.026
|
| [4] |
张丹妮. 黛力新治疗对改善原发性高血压血压变异和晨峰的效果研究[D]. 遵义: 遵义医科大学, 2020.
|
| [5] |
MALDARINE J S, SANCHES B D A, SANTOS V A, et al. Postnatal exposure to finasteride causes different effects on the prostate of male and female gerbils[J]. Cell Biol Int, 2020, 44(6): 1341-1352. doi: 10.1002/cbin.11328
|
| [6] |
ABT D, MÜLLHAUPT G, HECHELHAMMER L, et al. Prostatic artery embolisation versus transurethral resection of the prostate for benign prostatic hyperplasia: 2-yr outcomes of a randomised, open-label, single-centre trial[J]. Eur Urol, 2021, 80(1): 34-42. doi: 10.1016/j.eururo.2021.02.008
|
| [7] |
XIAO K W, ZHOU L, HE Q, et al. Transurethral endoscopic enucleation of the prostate using a diode laser versus bipolar plasmakinetic for benign prostatic obstruction: a meta-analysis[J]. Lasers Med Sci, 2020, 35(5): 1159-1169. doi: 10.1007/s10103-020-02949-9
|
| [8] |
中华医学会男科学分会, 良性前列腺增生诊疗及健康管理指南编写组. 良性前列腺增生诊疗及健康管理指南[J]. 中华男科学杂志, 2022, 28(4): 356-365. https://xuewen.cnki.net/CCND-YSBZ20220707B060.html
|
| [9] |
GARDEN E B, RAVIVARAPU K T, LEVY M, et al. The utilization and safety of same-day discharge after transurethral benign prostatic hyperplasia surgery: a case-control, matched analysis of a national cohort[J]. Urology, 2022, 165: 59-66. doi: 10.1016/j.urology.2022.01.037
|
| [10] |
STAMIS S A, HEATH E I, LUCAS S, et al. Alcohol dehydrogenase expression patterns in normal prostate, benign prostatic hyperplasia, and prostatic adenocarcinoma in African American and Caucasian men[J]. Prostate, 2022, 82(6): 666-675. doi: 10.1002/pros.24310
|
| [11] |
SHIMIZU S, NAGAO Y, SHIMIZU T, et al. Therapeutic effects of losartan on prostatic hyperplasia in spontaneously hypertensive rats[J]. Life Sci, 2021, 266: 118924. doi: 10.1016/j.lfs.2020.118924
|
| [12] |
宋蕊, 高双友, 李敏, 等. 良性前列腺增生合并高血压患者24小时动态血压与其夜尿症的相关性[J]. 中国煤炭工业医学杂志, 2021, 24(5): 523-526. https://www.cnki.com.cn/Article/CJFDTOTAL-ZMGY202105016.htm
|
| [13] |
占达良, 王晟, 张耿. 非杓型高血压合并良性前列腺增生患者联合使用替米沙坦和非那雄胺的疗效[J]. 中国临床研究, 2019, 32(7): 919-922. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGCK201907013.htm
|
| [14] |
SARKAR G, GAIKWAD V B, SHARMA A, et al. Fixed-dose combination of metoprolol, telmisartan, and chlorthalidone for essential hypertension in adults with stable coronary artery disease: PhaseIII study[J]. Adv Ther, 2022, 39(2): 923-942. doi: 10.1007/s12325-021-01971-9
|
| [15] |
JIN X, KIM M H, HAN K H, et al. Efficacy and safety of co-administered telmisartan/amlodipine and rosuvastatin in subjects with hypertension and dyslipidemia[J]. J Clin Hypertens, 2020, 22(10): 1835-1845. doi: 10.1111/jch.13893
|
| [16] |
MALDARINE J S, SANCHES B D A, CABRAL ÁS, et al. Prenatal exposure to finasteride promotes sex-specific changes in gerbil prostate development[J]. Reprod Fertil Dev, 2019, 31(11): 1719-1729. doi: 10.1071/RD19106
|
| [17] |
ANGRIMANI D S R, FRANCISCHINI M C P, BRITO M M, et al. Prostatic hyperplasia: Vascularization, hemodynamic and hormonal analysis of dogs treated with finasteride or orchiectomy[J]. PLoS One, 2020, 15(6): e0234714. doi: 10.1371/journal.pone.0234714
|
| [18] |
SHOJI S, HANADA I, OTAKI T, et al. Functional outcomes of transurethral thulium laser enucleation versus bipolar transurethral resection for benign prostatic hyperplasia over a period of 12months: a prospective randomized study[J]. Int J Urol, 2020, 27(11): 974-980. doi: 10.1111/iju.14341
|
| [19] |
CADEDDU J A. Re: a prospective comparative analysis of robot-assisted vs open simple prostatectomy for benign prostatic hyperplasia[J]. J Urol, 2019, 202(1): 12-13.
|
| [20] |
WEN Z, DENG X Z, WANG L, et al. Efficacy and safety of transurethral thulium laser enucleation versus robot-assisted prostatectomy for large-volume benign prostatic hyperplasia: a systematic review and meta-analysis[J]. J Robot Surg, 2023, 17(6): 2633-2646. doi: 10.1007/s11701-023-01715-7
|
| [21] |
XIAO K W, ZHOU L, HE Q, et al. Enucleation of the prostate for benign prostatic hyperplasia thulium laser versus holmium laser: a systematic review and meta-analysis[J]. Lasers Med Sci, 2019, 34(4): 815-826. doi: 10.1007/s10103-018-02697-x
|
| [22] |
HARTUNG F O, KOWALEWSKI K F, VON HARDENBERG J, et al. Holmium versus thulium laser enucleation of the prostate: a systematic review and meta-analysis of randomized controlled trials[J]. Eur Urol Focus, 2022, 8(2): 545-554. doi: 10.1016/j.euf.2021.03.024
|
© 2020 《实用临床医药杂志》编辑部
Address: 江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室China Pos: 225009Tel: 0514-87978917、87978989、87978807
Supported by:
Beijing Renhe Information Technology Co., Ltd.
苏公网安备 32100302010246号
DownLoad: